Secondary prevention of acute coronary syndromes: Are we following correctly the guidelines?;La prevenzione secondaria delle sindromi coronariche acute: Stiamo disattendendo le linee guida?

Giornale Italiano di Cardiologia

Volumn 7, Issue 3, 2006, Pages 176-185

  Casella, Gianni ^a   Greco, Cesare ^b   Maggioni, Aldo P ^c   Di Pasquale, Giuseppe ^a  

^a MAGGIORE HOSPITAL   (Italy)

^b SAN GIOVANNI ADDOLORATA HOSPITAL   (Italy)

^c ANMCO RESEARCH CENTER   (Italy)

Author keywords

Acute coronary syndromes; Guidelines; Prevention; Therapy

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PERINDOPRIL; PLACEBO; RAMIPRIL; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; FIBRINOLYTIC AGENT; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ARTICLE; CAUSE OF DEATH; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HOSPITAL DISCHARGE; HUMAN; MORBIDITY; MORTALITY; PATIENT EDUCATION; PRACTICE GUIDELINE; PRIMARY PREVENTION; PROGNOSIS; RISK ASSESSMENT; RISK REDUCTION; SECONDARY PREVENTION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; ACUTE DISEASE; ALGORITHM; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DIFFERENTIAL DIAGNOSIS; ELECTROCARDIOGRAPHY; FORECASTING; HEART INFARCTION; REVIEW; SYNDROME; THORAX PAIN; UNSTABLE ANGINA PECTORIS;

ACUTE DISEASE; ADRENERGIC BETA-ANTAGONISTS; ALGORITHMS; ANGINA, UNSTABLE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTILIPEMIC AGENTS; ASPIRIN; CHEST PAIN; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; DIAGNOSIS, DIFFERENTIAL; ELECTROCARDIOGRAPHY; EVIDENCE-BASED MEDICINE; FIBRINOLYTIC AGENTS; FORECASTING; GUIDELINE ADHERENCE; HUMANS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES; PROGNOSIS; RISK ASSESSMENT; SYNDROME; TICLOPIDINE;

EID: 33645729983     PISSN: 18276806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Bonow RO, Smaha LA, Smith SC Jr, Mensah GA, Lenfant C. World Heart Day 2002. The international burden of cardiovascular disease: responding to the emerging global epidemic. Circulation 2002; 106: 1602-5.
2. Yusuf S. Two decades of progress in preventing vascular disease. Lancet 2002; 360: 2-3.
3. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001; 104: 365-72.
4. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: executive summary. A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). J Am Coll Cardiol 2004; 44: 671-719.
5. Bertrand ME, Simoons ML, Fox KA, et al, for the Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology. Management of acute coronary syndrome in patients presenting without persistent ST-segment elevation. Eur Heart J 2002; 23: 1809-40.
6. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction - 2002: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the management of patients with unstable angina). Circulation 2002; 106: 1893-900.
7. Mukherjee D. Optimizing management of patients with coronary artery disease: how do we get there? Eur Heart J 2005; 26: 1147-9.
8. Mukherjee D, Fang J, Chetcuti S, Moscucci M, Kline-Rogers E, Eagle KA. Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromes. Circulation 2004; 109: 745-9.
9. Hlatky MA. Underuse of evidence-based therapies. Circulation 2004; 110: 644-5.
10. Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta-blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999; 318: 1730-7.
11. Latini R, Maggioni A, Flather M, Sleight P, Tognoni G. ACE inhibitor use in patients with myocardial infarction: summary of evidence from clinical trials. Circulation 1995; 92: 3132-7.
12. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-53.
13. The European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-8.
14. Braunwald E, Domanski MJ, Fowler SE, et al, for the PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351: 2058-68.
15. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
16. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57.
17. Cannon CP, Braunwald E, McCabe CH, et al, for the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-504.
18. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
19. Marchioli R, Barzi F, Bomba E, et al, for the GISSI-Prevenzione Investigators. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002; 105: 1897-903.
20. The Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
21. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
22. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, for the Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
23. Casella G, Ottani F, Pavesi PC, et al. Safety and efficacy evaluation of clopidogrel compared to ticlopidine after stent implantation: an updated meta-analysis. Ital Heart J 2003; 4: 677-84.
24. Mehta SR, Yusuf S, Peters RJ, et al, for the Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-33.
25. Silber S, Albertsson P, Aviles FF, et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005; 26: 804-47.
26. Steinhubl SR, Berger PB, Mann JT 3rd, et al, for the CREDO Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomised controlled trial. JAMA 2002; 288: 2411-20.
27. Bassand JP, Priori S, Tendera M. Evidence-based vs "impressionist" medicine: how best to implement guidelines. Eur Heart J 2005; 26: 1155-8.
28. Tran CT, Lee DS, Flintoft VF, et al, for the Canadian Cardiovascular Outcomes Research Team/Canadian Cardiovascular Society; Acute Myocardial Infarction Quality Indicator Panel. CCORT/CCS quality indicators for acute myocardial infarction care. Can J Cardiol 2003; 19: 38-45.
29. Califf RM, Peterson ED, Gibbons RJ, et al. Integrating quality into the cycle of therapeutic development. J Am Coll Cardiol 2002; 40: 1895-901.
30. Savonitto S, Klugmann S. Sindromi coronariche acute senza opraslivellamento del tratto ST. Dai trial clinici, alle linee guida, alla pratica clinica in Italia: necessità di chiudere il cerchio. Ital Heart J Suppl 2004; 5: 167-76.
31. Hamm CW, Bertrand ME, Braunwald E. Acute coronary syndrome without ST elevation: implementation of new guidelines. Lancet 2001; 358: 1533-8.
32. Gottwik M, Zahn R, Schiele R, et al, for the Myocardial Infarction Registry (MIR) Study Groups. Differences in treatment and outcome of patients with acute myocardial infarction admitted to hospitals with compared to without departments of cardiology: results from the pooled data of the Maximal Individual Therapy in Acute Myocardial Infarction (MITRA 1 + 2) Registries and the Myocardial Infarction Registry (MIR). Eur Heart J 2001; 22: 1794-801.
33. Allen LA, O'Donnell CJ, Giugliano RP, Camargo CA Jr, Lloyd-Jones DM. Care concordant with guidelines predicts decreased long-term mortality in patients with unstable angina and non-ST-elevation myocardial infarction. Am J Cardiol 2004; 93: 1218-22,
34. Di Chiara A, Chiarella F, Savonitto S, et al, on behalf of the BLITZ Investigators. Epidemiology of acute myocardial infarction in the Italian CCU network: the BLITZ study. Eur Heart J 2003; 24: 1616-29.
35. The Registro Osservazionale Angina Instabile (ROSAI-2) Investigators. Treatment modalities of non-ST-elevation acute coronary syndromes in the real world. Results of the prospective ROSAI-2 registry. Ital Heart J 2003; 4: 782-90.
36. Di Chiara A, Fresco C, Savonitto S, et al. Epidemiology of non-ST elevation acute coronary syndromes in the Italian cardiology network: the BLITZ-2 study. Eur Heart J 2006; 27: 393-405.
37. Pavesi PC, Ottani F, Bologna F, Gaddi O, Alboni P, Galvani M, a nome dei Ricercatori dello Studio AICARE-2. Epidemiologia delle sindromi coronariche acute nelle cardiologie dell'Emilia Romagna: lo studio AI-CARE2. Ital Heart J Suppl 2003; 4: 733-44.
38. Califf RM, DeLong ER, Ostbye T, et al. Under-use of aspirin in a referral population with documented coronary artery disease. Am J Cardiol 2002; 89: 653-61.
39. Budnitz D, Neuman WR. Underuse of beta-blockers following myocardial infarction. (letter) JAMA 2001; 285: 1013.
40. Hemingway H, Crook AM, Feder G, et al. Underuse of coronary revascularization procedures in patients considered appropriate candidates for revascularization. N Engl J Med 2001; 344: 645-54.
41. Ohman EM, Roe MT, Smith SC Jr, et al, for the CRUSADE Investigators. Care of non-ST-segment elevation patients: insights from the CRUSADE national quality improvement initiative. Am Heart J 2004; 148 (Suppl): S34-S39.
42. Roe MT, Parsons LS, Pollack CV Jr, et al, for the National Registry of Myocardial Infarction Investigators. Quality of care by classification of myocardial infarction. Treatment patterns for ST-segment elevation vs non-ST-segment elevation myocardial infarction. Arch Intern Med 2005; 165: 1630-6.
43. Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients. The treatment-risk paradox. JAMA 2004; 291: 1864-70.
44. Peterson E, Parsons L, Pollack C, Newby LK. Variation of AMI care quality across 1085 US hospitals and its association with hospital mortality rates. (abstr) Circulation 2002; 106:II-722.
45. Kulkarni S, Li Y, Alexander KP, et al. Elderly not receiving recommended early interventions for acute coronary syndromes: update from CRUSADE. (abstr) Am J Geriatr Cardiol 2003; 12: 135.
46. Casella G, Di Pasquale G. Rivascolarizzazione coronarica: quale, a chi, come e quando? Ital Heart J 2005; 6 (Suppl 3): 28S-35S.
47. De Servi S, Cavallini C, Dellavalle A, et al, for the ROSAI-2 Investigators. Non-ST-elevation acute coronary syndrome in the elderly: treatment strategies and 30-day outcome. Am Heart J 2004; 147: 830-6.
48. Carruthers KF, Dabbous OH, Flather MD, et al, on behalf of the GRACE Investigators. Contemporary management of acute coronary syndromes: does the practice match the evidence? The Global Registry of Acute Coronary Events (GRACE). Heart 2005; 91: 290-8.
49. Danchin N, Grenier O, Ferrieres J, Cantet C, Cambou JP. Use of secondary preventive drugs in patients with acute coronary syndromes treated medically or with coronary angioplasty: results from the nationwide French PREVENIR survey. Heart 2002; 88: 159-62.
50. Steg PG, Iung B, Feldman LJ, et al. Impact of availability and use of coronary interventions on the prescription of aspirin and lipid lowering treatment after acute coronary syndromes. Heart 2002; 88: 20-4.
51. Burger W, Chemnitius JM, Kneissl GD, Rucker G. Low-dose aspirin for secondary cardiovascular prevention: cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis. J Intern Med 2005; 257: 399-414.
52. Ferrari E, Benhamou M, Cerboni P, Marcel B. Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol 2005; 45: 456-9.
53. Di Pasquale G, Casella G. Attualità nel trattamento dell'infarto miocardico acuto. Annali delta Sanità Pubblica 2004; 1: 1-8.
54. Mehta RH, Montoye CK, Gallogly M, et al, for the GAP Steering Committee of the American College of Cardiology. Improving quality of care for acute myocardial infarction: the Guidelines Applied in Practice (GAP) initiative. JAMA 2002; 287: 1269-76.
55. Fonarow GC, Gawlinski A, Moughrabi S, Tillisch JH. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol 2001; 87: 819-22.
56. Federazione Italiana di Cardiologia, Società Italiana di Cardiologia Invasiva. Documento di Consenso. La rete interospedaliera per l'emergenza coronarica. Ital Heart J Suppl 2005; 6 (Suppl 6): 5S-26S.